Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Volution predicts forecast-beating second half, shares jump

(Sharecast News) - Shares in Volution Group rallied on Thursday, after the engineering firm said full-year earnings were on track to beat forecasts. The firm, a specialist in energy efficient indoor air quality solutions, said revenues in the six months to 31 January had strengthened nearly 9% to £187.8m.

It said sales had been driven by organic growth of 4% as well as its £144m acquisition of Australia's Fantech, which completed in early December.

Adjusted operating profits rose 10.4% to £42.6m, though pre-tax profits fell 11.3% to £25.7m, primarily due to costs associated with the Fantech deal.

Ronnie George, chief executive, said: "We delivered a strong performance in the first half, with good organic growth supplemented by two months of contribution of Fantech, our largest acquisition to date.

"Although the general economic backdrop remained weak, we continued to benefit from our structural growth drivers: ever tightening building regulations, increasing awareness of the importance of air quality and the need to reduce costs."

George added that the firm had "good momentum" going into the second half, and as a result, now expects full-year earnings to be ahead of consensus.

The market is currently forecasting adjusted earnings per share in the range of 30.3p to 31.3p, with consensus for 30.8p. Interim adjusted basic EPS was 15.3p, up 11.7%.

As at 0930 GMT, shares in Volution had put on 10% at 570.54p.

David Farrell, analyst at Jefferies, said: "Organic revenue growth of 4% is right in the middle of the target range, but there is improving momentum heading in the second half, which is important to note. Cash conversion is yet again strong, and leverage is already down to 1.5x following December's acquisition. We expect a strong share price reaction after drifting from November highs."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.